|
1
|
Li S, Li C and Fang Z: MicroRNA 214
inhibits adipocyte enhancer-binding protein 1 activity and
increases the sensitivity of chemotherapy in colorectal cancer.
Oncol Lett. 17:55–62. 2019.PubMed/NCBI
|
|
2
|
Tie Y, Chen C, Yang Y, Qian Z, Yuan H,
Wang H, Tang H, Peng Y, Du X and Liu B: Upregulation of let-7f-5p
promotes chemotherapeutic resistance in colorectal cancer by
directly repressing repressing several pro-apoptotic proteins.
Oncol Lett. 15:8695–8702. 2018.PubMed/NCBI
|
|
3
|
Lo Russo G, Proto C and Garassino MC:
Afatinib in the treatment of squamous non-small cell CRC: A new
frontier or an old mistake? Transl Lung Cancer Res. 5:110–114.
2016.PubMed/NCBI
|
|
4
|
Kazandjian D, Suzman DL, Blumenthal G,
Mushti S, He K, Libeg M, Keegan P and Pazdur R: FDA approval
summary: Nivolumab for the treatment of metastatic non-small cell
CRC with progression on or after platinum-based chemotherapy.
Oncologist. 21:634–642. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Antonia S, Goldberg SB, Balmanoukian A,
Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel
JJ and Rizvi NA: Safety and antitumour activity of durvalumab plus
tremelimumab in non-small cell CRC: A multicentre, phase 1b study.
Lancet Oncol. 17:299–308. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou YY, Hu ZG, Zeng FJ and Han J:
Clinical profile of cyclooxygenase-2 inhibitors in treating
non-small cell CRC: A meta-analysis of nine randomized clinical
trials. PLoS One. 11:e01519392016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fenchel K, Sellmann L and Dempke WC:
Overall survival in non-small cell CRC-what is clinically
meaningful? Transl Lung Cancer Res. 5:115–119. 2016.PubMed/NCBI
|
|
8
|
Shi X, Xiao L, Mao X, He J, Ding Y, Huang
J, Peng C and Xu Z: miR-205-5p mediated downregulation of PTEN
contributes to cisplatin resistance in C13K human ovarian cancer
cells. Front Genet. 9:5552018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu D, Lu P, Mi X and Miao J:
Downregulation of miR-503 contributes to the development of drug
resistance in ovarian cancer by targeting pi3K p85. Arch Gynecol
Obstet. 297:699–707. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang R, Lin JY and Chi YJ: miR-519d
reduces the 5-fluorouracil resistance in colorectal cancer cells by
down-regulating the expression of CCND1. Eur Rev Med Pharmacol Sci.
22:2869–2875. 2018.PubMed/NCBI
|
|
13
|
Paliouras AR, Monteverde T and Garofalo M:
Oncogene-induced regulation of microrna expression: Implications
for cancer initiation, progression and therapy. Cancer Lett.
421:152–160. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang C, Qian D, Zhao H, Lv N, Yu P and
Sun Z: miR17 improves insulin sensitivity through inhibiting
expression of ask1 and anti-inflammation of macrophages. Biomed
Pharmacother. 100:448–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rupaimoole R, Calin GA, Lopez-Berestein G
and Sood AK: miRNA deregulation in cancer cells and the tumor
microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yin W, Shi L and Mao Y: miR-194 regulates
nasopharyngeal carcinoma progression by modulating MAP3K3
expression. FEBS Open Bio. 9:43–52. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaalund SS, Venø MT, Bak M, Møller RS,
Laursen H, Madsen F, Broholm H, Quistorff B, Uldall P, Tommerup N,
et al: Aberrant expression of miR-218 and miR-204 in human mesial
temporal lobe epilepsy and hippocampal sclerosis-convergence on
axonal guidance. Epilepsia. 55:2017–2027. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen J and Li M: Microrna-744 inhibits
cellular proliferation and invasion of colorectal cancer by
directly targeting oncogene notch1. Oncol Res. 2018. View Article : Google Scholar
|
|
20
|
Zhang Q, Zhang B, Sun L, Yan Q, Zhang Y,
Zhang Z, Su Y and Wang C: MicroRNA-130b targets PTEN to induce
resistance to cisplatin in lung cancer cells by activating
Wnt/β-catenin pathway. Cell Biochem Funct. 36:194–202. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao Y, Ma H, Gao C, Lv Y, Chen X, Xu R,
Sun M, Liu X, Lu X, Pei X and Li P: Tumor-promoting properties of
miR-8084 in breast cancer through enhancing proliferation,
suppressing apoptosis and inducing epithelial-mesenchymal
transition. J Transl Med. 16:382018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu Y, Guo X, Wang J, Liu Y, Gao H, Fan H,
Nong X, Yang X, Liu M, Li S and Tang H: A novel microrna identified
in hepatocellular carcinomas is responsive to lef1 and facilitates
proliferation and epithelial-mesenchymal transition via targeting
of nfix. Oncogenesis. 7:222018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xia D, Tian S, Chen Z, Qin W and Liu Q:
miR302a inhibits the proliferation of esophageal cancer cells
through the mapk and PI3K/Akt signaling pathways. Oncol Lett.
15:3937–3943. 2018.PubMed/NCBI
|
|
24
|
Yu Z, Xu N, Yang W, Liu Y and Yan F:
Microrna-411 promoted the osteosarcoma progression by suppressing
MTSS1 expression. Environ Sci Pollut Res Int. 25:12064–12071. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun X, Zhai H, Chen X, Kong R and Zhang X:
MicroRNA-1271 suppresses the proliferation and invasion of
colorectal cancer cells by regulating metadherin/Wnt signaling. J
Biochem Mol Toxicol. 32:2018.Doi: 10.1002/jbt.22028. View Article : Google Scholar
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xing F, Wang S and Zhou J: The expression
of microRNA-598 inhibits ovarian cancer cell proliferation and
metastasis by targeting URI. Mol Ther Oncolytics. 12:9–15. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y and Qin H: miR-338-3p targets RAB23
and suppresses tumorigenicity of prostate cancer cells. Am J Cancer
Res. 8:2564–2574. 2018.PubMed/NCBI
|
|
29
|
Weng L, Ma J, Jia YP, Wu SQ, Liu BY, Cao
Y, Yin X, Shang MY and Mao AW: miR-4262 promotes cell apoptosis and
inhibits proliferation of colon cancer cells: Involvement of
GALNT4. Am J Transl Res. 10:3969–3977. 2018.PubMed/NCBI
|
|
30
|
Toiyama Y, Okugawa Y, Fleshman J, Richard
Boland C and Goel A: MicroRNAs as potential liquid biopsy
biomarkers in colorectal cancer: A systematic review. Biochim
Biophys Acta Rev Cancer. 1870:274–282. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang M, Shan X, Zhou X, Qiu T, Zhu W, Ding
Y, Shu Y and Liu P: miR-1271 regulates cisplatin resistance of
human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and
BCL2. Anticancer Agents Med Chem. 14:884–891. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shao Q, Zhang P, Ma Y, Lu Z, Meng J, Li H,
Wang X, Chen D, Zhang M, Han Y, et al: Microrna-139-5p affects
cisplatin sensitivity in human nasopharyngeal carcinoma cells by
regulating the epithelial-to-mesenchymal transition. Gene.
652:48–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang Y, Liu L, Zhang Y, Guan H, Wu J, Zhu
X, Yuan J and Li M: miR-503 targets pi3K p85 and IKK-beta and
suppresses progression of non-small cell CRC. Int J Cancer.
135:1531–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen Z, Gao YJ, Hou RZ, Ding DY, Song DF,
Wang DY and Feng Y: MicroRNA-206 facilitates gastric cancer cell
apoptosis and suppresses cisplatin resistance by targeting MAPK2
signaling pathway. Eur Rev Med Pharmacol Sci. 23:171–180.
2019.PubMed/NCBI
|
|
35
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li J, Sun H, Liu T and Kong J:
MicroRNA-423 promotes proliferation, migration and invasion and
induces chemoresistance of endometrial cancer cells. Exp Ther Med.
16:4213–4224. 2018.PubMed/NCBI
|
|
37
|
Wei Y, Wu S, Xu W, Liang Y, Li Y, Zhao W
and Wu J: Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses
cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
Thorac Cancer. 8:26–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li L, Sun JX, Wang XQ, Liu XK, Chen XX,
Zhang B, He ZD, Liu DZ, Chen LX, Wang LW and Huang Z:
Notoginsenoside R7 suppresses cervical cancer via
PI3K/PTEN/Akt/mTOR signaling. Oncotarget. 8:109487–109496. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fujishita T, Kojima Y, Kajino-Sakamoto R,
Taketo MM and Aoki M: Tumor microenvironment confers mTOR inhibitor
resistance in invasive intestinal adenocarcinoma. Oncogene.
36:6480–6489. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang C, Liu E, Li W, Cui J and Li T:
miR-3188 inhibits non-small cell lung cancer cell proliferation
through FOXO1-mediated mTOR-p-PI3K/AKT-c-JUN signaling pathway.
Front Pharmacol Dec. 9:13622018. View Article : Google Scholar
|
|
41
|
Gao S, Zhao Z, Wu R, Wu L, Tian X and
Zhang Z: miR-146b inhibits autophagy in prostate cancer through
affecting PTEN/AKT/mTOR signaling pathway. Aging (Albany NY).
11:2842019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Song L, Zhou Z, Gan Y, Li P, Xu Y, Zhang
Z, Luo F, Xu J, Zhou Q and Dai F: Long noncoding RNA OIP5-AS1
causes cisplatin resistance in osteosarcoma through inducing the
LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p.
J Cell Biochem. Dec 11–2018.(Epub ahead of print). doi:
10.1002/jcb.28244.
|
